Shanghai, China

Aiyun Song

This inventor holds 1 USPTO granted patent. Top assignees: Guangzhou Joyo Pharmatech Co., Ltd, Shanghai Jia Tan Pharmatech Co., Ltd.. Active years: 2026.


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aiyun Song: Innovator in Cancer Treatment

Introduction

Aiyun Song is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for various types of cancer. His innovative work has the potential to impact the lives of many patients suffering from PIK3CA-mutated cancers.

Latest Patents

Aiyun Song holds a patent for the "Application of pyrido[1,2-a]pyrimidinone analog." This patent involves the application of a pyrido[1,2-a]pyrimidinone analog or a pharmaceutically acceptable salt thereof in the preparation of a drug. The drug is designed to treat and/or prevent several types of cancer, including PIK3CA-mutated breast cancer, ovarian cancer, endometrial cancer, cervical cancer, and bladder cancer. He has 1 patent to his name.

Career Highlights

Throughout his career, Aiyun Song has worked with various companies, including Guangzhou Joyo Pharmatech Co., Ltd and Shanghai Jia Tan Pharmatech Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in cancer treatment.

Collaborations

Aiyun has collaborated with several professionals in his field, including Yongguo Li and Wei Wei. These partnerships have fostered an environment of innovation and have led to advancements in cancer therapies.

Conclusion

Aiyun Song is a dedicated inventor whose work in cancer treatment showcases his commitment to improving patient outcomes. His innovative patent and collaborations highlight his significant contributions to the pharmaceutical industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…